4-Pro-MET (C16H22N2O2, MW 274.364 g/mol) sits on the classic tryptamine scaffold ? an indole ring fused to an ethylamine side chain ? but with two twists: a propionyloxy ester at position 4 and asymmetric N-methyl-N-ethyl substitution on the terminal nitrogen. These two modifications explain why 4-Pro-MET works as a prodrug, why it outlasts its active metabolite on the shelf, and how it fits into the wider tryptamine family. We'll walk through the chemistry in plain language.

Every tryptamine shares the same molecular skeleton: an indole ring (benzene fused to pyrrole) connected to a two-carbon ethylamine side chain. This core ? 2-(1H-indol-3-yl)ethylamine ? is also the backbone of serotonin, melatonin, DMT, and psilocybin. It contains exactly 10 carbon atoms and 2 nitrogen atoms, and it's the essential pharmacophore (the minimum structure needed for biological activity) for serotonin receptor binding.

The indole ring is aromatic and planar. Think of it as the rigid frame that slots into serotonin receptor binding pockets. The ethylamine side chain, by contrast, is flexible ? it's the tail that interacts with amino acid residues inside the receptor's transmembrane domains. Change either part, ring or chain, and you shift how the molecule binds and which receptor subtypes it activates.

At position 4 of the indole ring, 4-Pro-MET carries a propionyloxy group (-O-CO-CH2-CH3) ? a three-carbon acyl ester, propanoic acid linked through an oxygen to the ring. This position matters because it corresponds to the 4-hydroxy position in the active metabolite 4-HO-MET and in natural compounds like psilocin.

Think of the propionyloxy group as a molecular cap. It shields the vulnerable 4-position from oxidation and doubles as the prodrug switch: when esterase enzymes cleave the ester bond, off comes the cap, and the active 4-hydroxy compound is exposed. The IUPAC name spells this out: [3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-yl] propanoate ? literally the propanoate ester of an indole bearing an ethyl-methyl-aminoethyl side chain.

On 4-Pro-MET's ethylamine side chain, the terminal nitrogen carries two different alkyl groups: one methyl (-CH3) and one ethyl (-C2H5). This asymmetric pattern defines the "MET" series (M=methyl, ET=ethyl) and sets it apart from the "DMT" series (N,N-dimethyl). The asymmetry creates a chiral environment around the nitrogen ? and that likely influences how the molecule orients itself inside receptor binding pockets.

Community researchers consistently describe MET-series compounds as producing a "clearer headspace" with more prominent visuals compared to their DMT-series counterparts. The exact pharmacological basis isn't fully worked out yet, but the asymmetric N-substitution is thought to alter binding dynamics at 5-HT2A and other serotonin receptors, potentially affecting signaling bias and receptor residence time.

4-Pro-MET follows established routes common to 4-acyloxy tryptamines. Two conceptual pathways: (a) direct esterification of 4-HO-MET with propionic anhydride or propionyl chloride, or (b) building the tryptamine from 4-acetoxyindole precursors through oxalyl chloride coupling, amine addition, and lithium aluminum hydride reduction (the Speeter-Anthony pathway Shulgin described for related compounds), then performing an ester exchange.

Shulgin documented 4-HO-MET synthesis in TiHKAL (entry #21) as a two-step process from 4-acetoxyindole. 4-Pro-MET itself never appeared in TiHKAL ? it first surfaced as a research chemical in 2025. For commercial distribution, it's typically converted to its fumarate salt, which offers better stability and crystalline properties.

Note: This section provides conceptual understanding only. Detailed synthesis instructions are intentionally omitted.